CICULATORY LEVELS OF RETINOL-BINDING PROTEIN 4 IN PATIENTS WITH TYPE 2 DIABETES, COMPLICATED BY NON-ALCOHOLIC FATTY LIVER DISEASE
DOI:
https://doi.org/10.21856/j-PEP.2014.2.01Keywords:
type 2 diabetes, non-alcoholic fatty liver disease, insulin resistance, retinolbinding protein 4Abstract
It was determined levels of retinol-binding protein 4 (RBP4) in the blood of patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease or its absence. In patients with type 2 diabetes was verified a significant increase of circulating levels of RBP4, the severity of which was significantly higher in non-alcoholic fatty liver disease, as well as their direct correlation with the presence of complications. The data obtained justify the use of indicators of circulatory levels of RBP4 as a new marker of the risk of non-alcoholic fatty liver disease in patients with type 2 diabetes and the selection of anti-diabetic therapy.
References
Chen W, Yu Z, Li Y. Zhonghua Gan Zang Bing Za Zhi 2000; 8:76-77.
Marchesini G, Brizi M, Bianchi G, et al. Diabetes 2001; 50:1844-1850.
Sharabi Y, Eldad A. Am J Med 2000; 109:171.
Pagano G, Pacini G, Musso G, et al. Hepatology 2002; 35:367-372.
Yang Q, Graham TE, Mody N, et al. Nature 2005;436:356-362.
Graham T, Yang Q, Bluher M, et al. N Engl J Med 2006; 354:2552-2563.
Rabe K, Lehrke M, Parhofer KG, Broedl UC. Mol Med 2008; 14:741-751.
Perseghin G, Lattuada G, De Cobelli F, et al. J Clin Endocrinol Metab 2007; 92:4883-4888.
Wu H, Jia W, Bao Y, et al. Diabetes Res Clin Pract 2008; 79:185-190.
Angulo P. N Engl J Med 2002; 346:1221-1231.
Clark JM, Brancati FL, Diehl AM. Gastroenterology 2002; 122:1649-1657.
Janes CH, Lindor KD. Ann Intern Med 1993;118:96-98.
Adams L, Angulo P, Lindor KD. CMAJ 2005;172:899-905.
Narciso-Schiavon JL, Schiavon LL, Carvalho-Filho RJ, et al. Sao Paulo Med J 2010; 128:342-347.
Chalasani N, Younossi Z, Lavine JE, et al. Hepatology 2012; 55(6): 2005-2023.
Matthews DR, Hoske JP, Rudensk AS, et al. Diabetologia 1985; 28: 412-419.
Katz A, Nambi SS, Mather K, et al. J Clin Endocr Metab 2000; 85: 2402-2410.
Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Semin Liver Dis 2001; 21:17-26.
Marchesini G, Brizi M, Morselli-Labate AM, et al. Am J Med 1999; 107:450-455.
Chang Y, Ryu S, Sung E, et al. Gut 2009; 58:1419-1425.
Marchesini G, Moscatiello S, Di Domizio S, Forlani S. J Clin Endocrinol Metab 2008; 93:74-80.
Adinolfi L, Gambardella M, Andreana A, et al.Hepatology 2001; 33: 1358-1364.
Park SH, Kim BI, Kim SH, et al. J Am Col Nutr 2007; 26(4):321-326.
Perseghin G, Bonfanti R, Magni S, et al. Am J Physiol Endocrinol Metab 2006; 291:E697-E703.
Gastaldelli A, Kozakova M, Hujlund K. Hepatology 2009; 49:1537-1544.
Targher G, Arcaro G. Atherosclerosis 2007; 191:235-240.
Toledo FG, Sniderman AD, Kelley DE. Diabetes Care 2006; 29:1845-1850.
Babak OJa, Kolesnikova EV. Suchasna Gastroenterologija 2009; 5:5-11.
Stefan N, Hennige AM, Staiger H, et al. Diabetes Care 2007; 30:1173-1178.
Perseghin G, Lattuada G, De Cobelli F, et al. J Clin Endocrinol Metab 2007; 2:4883-4888.
Wu H, Jia W, Bao Y, et al. Diabetes Res Clin Pract 2008; 79:185-190.
Bellentani S, Dalle GR, Suppini A, Marchesini G. Hepatology 2008; 47: 746-754.